DDInter1762 DDInter875
Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably develop resistance to these agents over time.[A229848, A229858, L32033] Temozolomide is an imidazotetrazine prodrug that is stable at acidic pH but undergoes spontaneous nonenzymatic hydrolysis at neutral or slightly basic pH; these properties allow for both oral and intravenous administration.[A229853, A229888, A229923, L32033] Following initial hydrolysis, further reactions liberate a highly reactive methyl diazonium cation capable of methylating various residues on adenosine and guanine bases leading to DNA lesions and eventual
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Temozolomide {u} (Compound) treats {v} (Disease) brain cancer
Temozolomide {u} (Compound) binds {v} (Gene) CYP3A4
Temozolomide {u} (Compound) upregulates {v} (Gene) CAPN1
Temozolomide {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Temozolomide {u} (Compound) downregulates {v} (Gene) ATP6V1D
Temozolomide {u} (Compound) causes {v} (Side Effect) Constipation
Temozolomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Temozolomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Temozolomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluorouracil
Temozolomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naxitamab
Temozolomide (Compound) treats brain cancer (Disease)
Temozolomide (Compound) binds CYP3A4 (Gene)
Temozolomide (Compound) upregulates CAPN1 (Gene)
Temozolomide (Compound) is included by Alkylating Activity (Pharmacologic Class)
Temozolomide (Compound) downregulates ATP6V1D (Gene)
Temozolomide (Compound) causes Constipation (Side Effect)
Temozolomide may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Temozolomide may cause a minor interaction that can limit clinical effects when taken with Enoxacin
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Fluorouracil
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab